New drug cocktail aims to outsmart resistant prostate cancer
NCT ID NCT06826768
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-phase trial tests a combination of two drugs—REGN5678 and cemiplimab—in 60 men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to find the safest dose and see if the drugs can help control the cancer. The study is currently recruiting at M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN5678 (a bispecific antibody targeting PSMA and CD28) plus cemiplimab (an anti-PD-1 immunotherapy)
What this could lead to
If successful, this could lead to a more effective and safer combination therapy for advanced prostate cancer that has stopped responding to standard treatments.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so the main goal is safety, not proof of effectiveness. The combination may cause significant immune-related side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.